Patterns of the rheumatic disease course in the setting of a new coronavirus infection
DOI: 10.32364/2587-6821-2021-5-2-84-88
V.V. Vakhlevskiy, V.V. Tyrenko, I.S. Svintsitskaya, E.V. Kryukov
S.M. Kirov Military Medical Academy, Saint-Petersburg, Russian Federation
The article describes the main pathophysiological mechanisms underlying the potential use of antirheumatic therapy in the new COVID-19 in patients with rheumatic diseases. Also, it summarizes current data on the risk and outcome of COVID-19 in patients with systemic autoimmune diseases. To date, there are no large randomized studies on the use of antirheumatic drugs in patients with rheumatic diseases in the setting of COVID-19. Besides, there is no convincing evidence that any disease-modifying antirheumatic drug (conventional synthetic, biological, or targeted synthetic) can prevent the development of a severe COVID-19 course. At the same time, the importance of concomitant pathology (hypertension, obesity, cardiovascular diseases, diabetes mellitus) and risk factors (smoking) in the development of a severe COVID-19 course in patients with rheumatic diseases is shown. The article presents possible options for initiating and continuing treatment with antirheumatic drugs in pa tients with rheumatic diseases, depending on the stage of the infectious disease process.
Keywords: COVID-19, rheumatic diseases, disease-modifying antirheumatic drug, interleukin, tumor necrosis factor, glucocorticosteroids.
For citation: Vakhlevskiy V.V., Tyrenko V.V., Svintsitskaya I.S., Kryukov E.V. Patterns of the rheumatic disease course in the setting of a new coronavirus infection. Russian Medical Inquiry. 2021;5(2):84–88. DOI: 10.32364/2587-6821-2021-5-2-84-88.
About the authors:
Vitaly V. Vakhlevsky — Adjunct Professor of the Department of Faculty Therapy, S.M. Kirov Military Medical Academy; 6Zh, Akademika Lebedeva str., St. Petersburg, 194044, Russian Federation; ORCID iD 0000-0001-5699-2414.
Vadim V. Tyrenko — Doct. of Sci. (Med.), Professor, Head of the Department of Faculty Therapy, S.M. Kirov Military Medical Academy; 6Zh, Academika Lebedevа str., St. Petersburg, 194044, Russian Federation; ORCID iD 0000-0002-0470-1109.
Irina S. Svintsitskaya — Cand. Of Sci. (Med.), senior lecturer of the Department of Faculty Therapy, S.M. Kirov Military Medical Academy; 6Zh, Academika Lebedevа str., St. Petersburg, 194044, Russian Federation; ORCID iD 0000-0002-1317-8276.
Evgeny V. Kryukov — Dr. of Sci. (Med), Professor, Head of the S.M. Kirov Military Medical Academy: 6Zh, Akademika Lebedeva str., St. Petersburg, 194044, Russian Federation; ORCID iD 0000-0002-8396-1936.
Contact information: Irina S. Svintsitskaya, e-mail: sonirinadoc@mail.ru. Financial Disclosure: no authors have a financial or property interest in any material or method mentioned. There is no conflict of interests. Received 29.01.2021, revised 25.02.2021, accepted 23.03.2021.
2. Гордеев А.В., Галушко Е.А., Насонов Е.Л. Концепция мультиморбидности в ревматологической практике. Научно-практическая ревматология. 2014;52(4):362–365. DOI: 10.14412/1995-4484-2014-362-365. [Gordeev A.V., Galushko E.A., Nasonov E.L. The concept of multimorbidity in rheumatologic practice. Rheumatology Science and Practice. 2014;52(4):362–365 (in Russ.)]. DOI: 10.14412/1995-4484-2014-362-365.
3. Насонова В.А., Фоломеева О.М., Эрдес Ш.Ф. Ревматические болезни в России в начале XXI века. Научно-практическая ревматология. 2003;1:6–10. DOI: 10.14412/1995-4484-2003-1124. [Nassonova V.A., Folomeyeva O.M., Erdesz S.F. Rheumatic diseases in Russia at the beginning of XXI century. Rheumatology Science and Practice. 2003;41(1):6–10 (in Russ.)]. DOI: 10.14412/1995-4484-2003-1124.
4. Velavan T.P., Meyer C.G. The COVID-19 epidemic. Trop Med Int Health. 2020;25(3):278–280. DOI: 10.1111/tmi.13383.
5. Tyrrell D.A., Bynoe M.L. Cultivation of viruses from a high proportion of patients with colds. Lancet. 1966;1(7428):76–77. DOI: 10.1016/s0140-6736 (66) 92364-6.
6. Schett G., Manger B., Simon D., Caporali R. COVID-19 revisiting inflammatory pathways of arthritis. Nat Rev Rheumatol. 2020;16(8):465–470. DOI: 10.1038/s41584-020-0451-z.
7. Козлов В.К. Цитокинотерапия: патогенетическая направленность и клиническая эффективность при инфекционных заболеваниях: руководство для врачей. СПб.: АльтерЭго; 2010. [Kozlov V.K. Cytokine therapy: pathogenetic focus and clinical efficacy in infectious diseases: a guide for physicians. SPb.: AlterEgo; 2010 (in Russ.)].
8. Liu Y., Yang Y., Zhang C. et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020;63(3):364–374. DOI: 10.1007/ s11427-020-1643-8.
9. Shi Y., Wang Y., Shao C. et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 2020;27(5):1451–1454. DOI: 10.1038/s41418-020-0530-3.
10. He F., Deng Y., Li W. Coronavirus disease 2019: What we know? J Med Virol. 2020;10.1002/jmv.25766. DOI: 10.1002/ jmv.25766.
11. Liu J., Zheng X., Tong Q. et al. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV. J Med Virol. 2020;92(5):491–494. DOI: 10.1002/jmv.25709.
12. Xu Z., Shi L., Wang Y. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–422. DOI: 10.1016/S2213-2600 (20) 30076-X.
13. Ruan Q., Yang K., Wang W. et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846–848. DOI: 10.1007/s00134-020-05991-x.
14. Li X., Geng M., Peng Y. et al. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020;10(2):102–108. DOI: 10.1016/j.jpha.2020.03.001.
15. Cossarizza A., De Biasi S., Guaraldi G. et al. Modena Covid-19 Working Group (MoCo19). SARSCoV-2, the Virus that Causes COVID-19: Cytometry and the New Challenge for Global Health. Cytometry A. 2020;97(4):340–343. DOI: 10.1002/cyto.a.24002.
16. Qin C., Zhou L., Hu Z. et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020;71(15):762–768. DOI: 10.1093/cid/ciaa248.
17. Skilton M.R., Celermajer D.S. The effects of obesity-related peptides on the vasculature. Curr Vasc Pharmacol. 2006;4(1):79–85. DOI: 10.2174/157016106775203135.
18. Xu Z., Shi L., Wang Y. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–422. DOI: 10.1016/S2213-2600 (20) 30076-X.
19. Gianfrancesco M., Hyrich K.L., Al-Adely S. et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859–866. DOI: 10.1136/annrheumdis-2020-217871.
20. Favalli E.G., Monti S., Ingegnoli F. et al. Incidence of COVID-19 in patients with rheumatic diseases treated with targeted immunosuppressive drugs: what can we learn from observational data? Arthritis Rheumatol. 2020;72:1600–1606. DOI: 10.1002/art.41388.
21. D’Silva K.M., Serling-Boyd N., Wallwork R. Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US "hot spot". Ann Rheum Dis. 2020;79:1156–1162. DOI: 10.1136/annrheumdis-2020-217888.
22. Gavrila A., Chan J.L., Yiannakouris N. et al. Serum adiponectin levels are inversely associated with overall and central fat distribution but are not directly regulated by acute fasting or leptin administration in humans: cross-sectional and interventional studies. J Clin Endocrinol Metab. 2003;88:4823–4831. DOI: 10.1210/jc.2003-030214.
23. Kern P.A., Di Gregorio G.B., Lu T. et al. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes. 2003;52:1779–1785.
24. Fasshauer M., Kralisch S., Klier M. et al. Interleukin-6 is a positive regulator of tumor necrosis factor alpha-induced adipose-related protein in 3T3-L1 adipocytes. FEBS Lett. 2004;560:153–157. DOI: 10.1016/S0014-5793 (04) 00096-1.
25. Caso F., Costa L., Ruscitti P. et al. Could Sars-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects? Autoimmun Rev. 2020;19:102524. DOI: 10.1016/j.autrev.2020.102524.
26. Vojdani A., Kharrazian D. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases. Clin Immunol. 2020;217:108480. DOI: 10.1016/j.clim.2020.108480.
27. Gagiannis D., Steinestel J., Hackenbroch C. et al. COVID-19-induced acute respiratory failure: an exacerbation of organ-specific autoimmunity? medRxiv. 2020. DOI: 10.1101/2020.04.27.20077180.
28. Zhou Y., Han T., Chen J. et al. Clinical and autoimmune characteristics of severe and critical cases of COVID-19. Clin Trans Sci. 2020;13(6):1077–1086. DOI: 10.1111/cts.12805.
29. Zhang Y., Xiao M., Zhang S. et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med. 2020;382:e38. DOI: 10.1056/NEJMc2007575.
30. Tan E.M. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol. 1989;44:93–151.
31. Im J.H., Chung M.H., Park Y.K. et al. Antinuclear antibodies in infectious diseases. Inf Disp. 2020;52:177–185. DOI: 10.1080/23744235.2019.1690676.
32. Litwin C.M., Binder S.R. ANA testing in the presence of acute and chronic infections. J Immunoassay Immunochem. 2016;37(5):439–452. DOI: 10.1080/15321819.2016.1174136.
33. Zhang X., Zhang Y., Qiao W. et al. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19. Int Immunopharmacol. 2020;86:106749. DOI: 10.1016/j.intimp.2020.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
